Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics (NASDAQ: RPRX) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.
Repros facts
|
Headquarters (founded) |
The Woodlands, Texas (1987) |
|
Market Cap |
$208.1 million |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month EBITDA |
($12.7 million) |
|
Management |
CEO Joseph Podolski (since 1992) |
|
Trailing-12-Month Return on Equity |
(69.9%) |
|
Cash/Debt |
$29.6 million / $0 |
|
Competitors |
Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 54% of the 131 members who have rated Repros believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star TerryHogan, succinctly summed up the Repros bear case for our community:
They're burning through cash like a former child-star on a [V]egas bender, and they're handing out shares like they're breath mints at a halitosis convention. They have no revenues to speak of (in fact they don't have any revenue at all). And while the latest announcement about their clinical trial isn't exactly a nail in the coffin, it could be a sign of greater malfeasance.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
